



b

Ultrasound in vascular liver diseases

Annalisa Berzigotti

Department for Visceral Surgery and Medicine Inselspital, Bern University Hospital, University of Bern Switzerland



US in Vascular liver diseases

- Budd-Chiari syndrome
- Portal vein thrombosis
- Congenital vascular malformations
- Porto-sinusoidal vascular disorder (PSVD)
- Hepatic artery diseases (aneurysm, thrombosis, A-V/A-P fistulas)
- Sinusoidal obstruction syndrome
- Radiation-induced liver disease
- Peliosis hepatis and sinusoidal dilatation







Systematic US approach to liver vessels



De Gottardi, Berzigotti et al. Ultraschall Med 2018

US in Vascular liver diseases

- Budd-Chiari syndrome
- Portal vein thrombosis
- Congenital vascular malformations
- Porto-sinusoidal vascular disorder (PSVD)
- Hepatic artery diseases (aneurysm, thrombosis)
- Sinusoidal obstruction syndrome
- Radiation-induced liver disease
- Peliosis hepatis and sinusoidal dilatation





Ultrasound/CDUS is the first line imaging technique to be used in this setting

High sensitivity (>90%) for thrombosis

Budd-Chiari syndrome

DEFINITION BCS is defined as the obstruction of hepatic venous outflow regardless of its causative mechanism or level of obstruction

Clinical impact very heterogeneous according to localization and timing. Hepatic venous web.

EPIDEMIOLOGY
Incidence 1.5 (0.68-2.17)/million year
Prevalence 4/million

- F/M=7/3



Potier, Hepato-Gastro, 2018. Van Wettere, Abd Radiol, 2018

Budd-Chiari syndrome

Acute or fulminant forms (7%)

- sudden onset hepatic impairment, ascites, pain, and often kidney failure
- hepatomegaly following obstruction of the three main hepatic veins.

Chronic or subacute forms

- most frequent presentation
- onset of the disease is slower in most patients
- few symptoms
- frequently impaired liver function
- portal hypertension is often present

The clinical diagnosis of BCS is difficult and should be suspected in the presence of:

 sudden development of ascites with increased liver volume and upper abdominal pain

- abundant high-protein ascites contrasting with moderately abnormal hepatic tests
- liver disease in a patient with a known thrombogenic condition
- fulminant hepatic failure accompanied by increased liver volume and ascites
- unexplained chronic liver disease

Budd-Chiari syndrome can be diagnosed by ultrasound



De Gottardi, Berzigotti, Ultraschall in Med, 2018

Direct signs of BCS: HV thrombus



Direct signs of BCS: IVC/hepatic vein system





«membrane» at the origin of the liver veins

Very difficulto to detect without CEUS

Bansal, Brit J Radiol, 2018

Chronic BCS: Hyperechoic cords (chronic fibrotic changes)



Hepatic veins: indirect signs of BCS

- Reversed flow in one of the HVs or a tract of it
- Large communication between one vein and another one
 «Bicolored hepatic vein»
- Large subcapsular veins draining in the IVC (compensatory)





Bargalló X et al. Am J Roent 2006



Chronic BCS

White arrow: right liver vein substituted by a fibrous cord

Yellow arrow: veno-venous collaterals

Red arrow: intrahepatic part of the IVC compressed by the liver parenchyma



Caudate lobe hypertrophy

- Sometimes grotesque aspect
- Caudate vein ≥ 3 mm (direct drain into IVC)



- Massive increase in
- size of the caudate
- lobe and
- hypotrophy of the anterior segments of the left liver lobe

CECT: IVC compressed in its intrahepatic part



Liver nodules in Budd-Chiari



- Very frequent 60–80% of patients on pathology
- Often large; often increase in size
- Mostly benign (FNH-like and large regenerative nodules)
- But HCC can appear: f-up and biopsy if increase in size Moucari et al. Gut 2008

CEUS to assess nodules in BCS



Basal US

Arterial phase

Venous phase

Portal circulation: normal



Portal vein thrombosis: definition and prevalence

Presence of a clot in any of the vessels of the PV axis:

- main portal vein trunk
- left and/or right intrahepatic PV branches
- splenic vein
- superior and/or inferior mesenteric veins

How frequent is it?

- 2.5 cases per 100'000 per year (without cirrhosis): EHPVO
 - 5 cases per 100 per year (in patients with cirrhosis)
 - 9 cases per 100 per year in PSVD

Northup et al. AASLD Guidance 2020

Clinical presentation: recent obstructive portal vein thrombosis



Clinical presentation in cirrhosis: obstructive portal vein thrombosis



How does it appear on US?



Echogenic material (hypo-, iso- or slightly hyperechogenic) within the vessel (better visualized in B-mode)

which can be <u>partially</u> (better seen on B mode) <u>or completely</u> occluded (flow better visualized by CDUS and PWUS)



Grey scale first; false negative if CDUS is used on first place!

Extent of PV Thrombosis: terminology according to the Baveno VII consensus



Elkrief et al. Lancet GH 2024



Complete PVT



Thrombosis of the splenic vein



US/CDUS is > 90% accurate in diagnosing PVT and SVT, but accuracy is lower for SMVT

Bach et al. Radiology 1996 Kuszyk et al. Radiology 1998

Once thrombosis is diagnosed, study of extension should be done with other imaging techniques



Avoiding US false positives (pseudothrombosis)

1- CDUS: reduce pulse repetition frequency (PRF) to minimum \rightarrow slow flows

- 2- Power Doppler US or angle-independent (not Doppler) flow imaging
- 3- CEUS if CDUS and other modes are not conclusive

Avoiding US false positives: use CEUS



Differentiating between benign PVT and neoplastic vascular invasion ("tumor in vein", "malignant" PVT)

US differentiation of benign vs. malignant PVT in patients with cirrhosis and HCC



CEUS for differentiating benign vs. malign portal vein thrombosis in the patients with cirrhosis and HCC



In 50 patients undergoing biopsy of the PV thrombus: better performance of CEUS vs CT scan in PVT detection (p < 0.0001) and thrombus characterization (p = 0.0001)

For neoplastic vascular invasion: Sens 98% CEUS vs 67.6% CT, specificity 100% CEUS, vs. 60% CT Rossi et al. Eur Radiol 2008

Piscaglia et al. Liver Traspl 2010

Partial PVT in a patient with HCC: benign



Obvious vascular invasion in a patient with HCC: MALIGNANT aspect on B mode and Doppler





Chronic PVT Calcifications of the wall: specific sign



Even if the vessel is patent, calcifications indicate that thrombosis had occurred Important in candidates to LT (PV wall more prone to dissection)

Cavernous Transformation



Hepatopetal collateral veins developing as soon as 15-30 days

after the onset of portal vein thrombosis.

Zhang, World J Gastroenterol, 2011; reviewed in Berzigotti et al. Nature Reviews Gastroenterol Hepatol 2014; De Gottardi, Berzigotti, et al. Ultraschall in Med, 2018; Rodrigues et al. Abdom Radiol 2018





<u>White arrow</u>: native portal vein shows complete old thrombosis replaced by fibrous tissue <u>Yellow arrow</u>: Cavernous transformation; note that a large dominant vessel (9 mm) is observed

Collaterals at the gallbladder wall



Take home messages: BCS and PVT

- Ultrasound/CDUS is the first line technique to be performed in case of suspected BCS and PVT, allowing > 90% accuracy in expert hands
- In difficult cases the use of CEUS allows a better evaluation of PV and HVs patency
- Look for signs of chronic disease (collateral circulation; calcifications in PVT)
- Assessment of extension of PVT needs to be done (CT or MRI); mapping of collaterals can be done with these techniques
- Imaging report should describe patency/thrombosis of all vessels at first examination AND in the follow-up

Arteroportal fistulas

Can occur at any level between the HA and the PV system. Intrahepatic APF are mostly iatrogenic/traumatic, but potentially reversible PH!

<u>B-mode</u>: anechoic rounded structures connecting a branch of the hepatic artery to a portal branch.

CDUS and PWUS:

- localized web of vascular channels
- hepatofugal flow in one/more portal vessels (according to size and site)
- pulsatile PV flow
- Difference \geq 25% in PI/RI in right vs. left HA

Lafortune et al. J Ultrasound Med 1986 Bolognesi et al. Radiology 2000

Intrahepatic A-P fistula

.20

.17





LARGE A-V FISTULA

1



00



SAMWASSM

Swiss National **Science Foundation**



Hepatological Diseases (ERN RARE-LIVER)



National Institutes of Health

LUCIE BOLTE STIFTUNG